The Novel Cellular Delivery Methods patent application appears to support PYC's CPP platform. It is for a cell penetrating peptide comprising a specific amino acid sequence, used in conjunction with a molecule of interest, be it a therapeutic agent or a diagnostic agent.
The VEGF-A patent application could certainly be relevant to Diabetic Retinopathy but I notice that, while DR was mentioned in a company presentation last August, it didn’t appear in the AGM presentation in November. In the Annual Report released in September, DR was again not mentioned, with possible common causes of blindness to be targeted said to include age-related macular degeneration and glaucoma.
VEGF-A as a target is certainly relevant to AMD but probably not for glaucoma.
This is simply my opinion.
CNS, page-48
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.3¢ |
Change
-0.003(1.72%) |
Mkt cap ! $653.2M | |||
| Open | High | Low | Value | Volume |
| 14.5¢ | 14.5¢ | 13.5¢ | $100.4K | 716.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 553982 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 1088220 | 16 |
View Market Depth
| Last trade - 11.55am 18/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |